Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Long-Term Deferred Tax (2016 - 2020)

BioRestorative Therapies (BRTX) has disclosed Long-Term Deferred Tax for 4 consecutive years, with $14.1 million as the latest value for Q4 2020.

  • For the quarter ending Q4 2020, Long-Term Deferred Tax rose 17.36% year-over-year to $14.1 million, compared with a TTM value of $14.1 million through Dec 2020, up 17.36%, and an annual FY2020 reading of $14.1 million, up 17.36% over the prior year.
  • Long-Term Deferred Tax was $14.1 million for Q4 2020 at BioRestorative Therapies, up from $12.0 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $14.1 million in Q4 2020 and bottomed at $5.4 million in Q4 2017.
  • Average Long-Term Deferred Tax over 4 years is $9.6 million, with a median of $9.4 million recorded in 2016.
  • The sharpest move saw Long-Term Deferred Tax decreased 20.69% in 2017, then rose 17.36% in 2020.
  • Year by year, Long-Term Deferred Tax stood at $6.8 million in 2016, then fell by 20.69% to $5.4 million in 2017, then surged by 123.42% to $12.0 million in 2019, then grew by 17.36% to $14.1 million in 2020.
  • Business Quant data shows Long-Term Deferred Tax for BRTX at $14.1 million in Q4 2020, $12.0 million in Q4 2019, and $5.4 million in Q4 2017.